ARCA biopharma
8001 Arista Place
Suite 200
Broomfield
Colorado
80021
United States
Tel: 720-940-2100
Fax: 720-208-9261
Website: http://www.arcabiopharma.com/
164 articles with ARCA biopharma
-
ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review
5/5/2022
ARCA biopharma, Inc. announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor.
-
ARCA biopharma Announces First Quarter 2022 Financial Results
5/2/2022
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2022 financial results and provided a corporate update.
-
ARCA biopharma Establishes Special Committee of the Board of Directors
4/18/2022
ARCA biopharma, Inc. today announced that its Board of Directors has established a Special Committee to evaluate strategic options for maximizing stockholder value.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Although the data suggests the vaccines are extremely effective and generally safe, analysis is still coming in about adverse events as well as effectiveness in specific patient populations.
-
ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial
3/31/2022
ARCA biopharma, Inc. (Nasdaq: ABIO), today announced results for ASPEN-COVID-19, a 160 patient Phase 2b clinical trial evaluating rNAPc2, a highly potent and specific inhibitor of tissue factor, as a potential treatment for patients hospitalized with COVID-19.
-
ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update
3/14/2022
ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, reported 2021 financial results and provided a corporate update.
-
Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2
1/4/2022
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the paper entitled “Dose Limiting, Adverse Event Associated Bradycardia with β-blocker Treatment of Atrial Fibrillation in the GENETIC-AF Trial” (William Abraham, et al) has been published in Heart Rhythm O2, a publication of the Hearth Rhythm Society.
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
-
ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19
12/2/2021
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing targeted therapies for cardiovascular diseases, today announced that enrollment has been completed in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19.
-
ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update
11/2/2021
ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, reported third quarter 2021 financial results and provided a corporate update.
-
Clinical Catch-Up: October 25-29
11/1/2021
Yet another busy week for clinical trial news. Here’s a look. -
ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data
10/28/2021
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today provided an update on the ASPEN-COVID-19 Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with severe COVID-19.
-
Clinical Catch-Up: September 13-17
9/20/2021
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look. -
ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
9/16/2021
ARCA biopharma, Inc. today announced that the first international patient has been enrolled in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19.
-
ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th
8/16/2021
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Jeff Dekker, Chief Financial Officer, will present at the Q3 Virtual Investor Summit being held August 17-18, 2021.
-
ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2
8/9/2021
ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that it has submitted a Patent Cooperation Treaty (PCT) patent application, following on previously submitted provisional patent applications, for the use of the Company’s developmental drug rNAPc2 to treat patients hospitalized with COVID-19.
-
ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update
8/4/2021
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2021 financial results and provided a corporate update.
-
ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th
7/9/2021
ARCA biopharma, Inc. today announced that Thomas Keuer , Chief Operating Officer, will present at the Access to Giving Virtual Investor Conference, which is being held virtually July 13-15, 2021.
-
Christopher Graybill Joins ARCA as Vice President, Clinical Development
5/5/2021
ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, announced that Christopher Graybill, Ph.D., has joined ARCA as Vice President, Clinical Development.